De doctor
Dr. Ahn optimum Jin-oncologist maior habetur cum in Seoul, Auster Korea.
- Jin-educationem se Ahn Dr.
-
- Doctoris summisque in medicina, Universitas Ulsan
- Magister summisque in medicina honoribus: Universitas Ulsan
- Bachelor of Medicine: Hanyang Universitas
- Dr. Ahn-fin ille experiences professional
-
- Inquisitorem adire ad Danafaber Cancri Instituti, Harvard Medical schola, USA
- Professor apud Oncology, UUCM AMC
- Suffragium Professor apud Oncology, UUCM AMC
- Instructor in orci UUCM AMC
- Societas in UUCM AMC
- Residentia in UUCM AMC
- Amet in UUCM AMC
hospitium
Asan Medical Center, Seoul, Auster Korea
specializationem?
- Pectus cancer
- & Os mollis TEXTUS SARCOMA
- Ceruicis cancer
- cancer corporis fabrica
- ovarian cancer
procedendi perfecerunt
- Pectus cancer curatio
- Curatio & os mollis TEXTUS SARCOMA
- Ceruicis cancer curatio
- Cancer curatio corporis fabrica
- Ovarian cancer curatio
Research Publications &
| Et Gemcitabine Docetaxel deducto Advanced pro textus mollis Herpesvirus hominis; National Retrospective Study. |
| Phase III, randomized, duplex caecus operationes efficaciam Latin Cum in id inquirerem, quid Salutis, et ex Vertebrata SB3 (trastuzumab Biosimilar), et aegros agitur et in Reference trastuzumab Neoadjuvant Therapy pro Humanum Angiokeratoma Corporis II augmentum factor-Positive |
| A randomized FACULTAS studium (XVIII) F ad Pet-Fluoroestradiol Predict Pathologic in estrogen receptor-Rich Postmenopausal Therapy Neoadjuvant Ad Pectus Cancri. |
| Ego consectetuer propagationis tempus, studio in c Met-tyrosine enzyme precursor SAR125844 provectus est in Asian cum aegris tumores solidum, inter Cum aegris augeri CARDIACUS cancer-MET. |
| Phase II, multicentre: a randomized iudicio eribulin gemcitabine versus plus quam primae gemcitabine paclitaxel plus-linea in aegris cum chemotherapy, negans HER2 metastatic pectus cancer. |
| De anima qualis est, TSU LXVIII: Compositum docetaxel et TSU LXVIII-, an oris antiangiogenic agente in metastatic pectus cancer cum aegris ante anthracycline tractata sunt. |
| A randomized 18f-FACULTAS studio fluoroestradiol alta emissionem tomography praedicere vitiatam responsio ad systemica neoadjuvant Lorem estrogen receptor-dives est in postmenopausal pectus cancer. |
| Cytoplasmic expressio altus motum coetus B1 (HMGB1) est tumor-consociata cum infiltrating lymphocytes (TILs) in pectus cancer. |
| Eventus de Long-term tyrosine enzyme precursor se discontinuandi in patientibus renum metastatic cell carcinoma. |
| Angiospermae Monogenic et determinantes SARCOMA periculum: an international geneticae studium. |
| Postero-generationem conferre mutationes, scire sequencing reveals Vicia narbonensis eximia everolimus responsionem. |
| Phase II iudicium Dei est in Asian lapatinib neoadjuvant letrozole et postmenopausal mulieres estrogen receptor (ER) et incrementum epidermalibus humana factor II (HER2) -positive pectus cancer [Neo-omnia-in]: Botanical in TILs, EF expressional mutatio afi |
| Rectum post postoperative fracturam, surgery ad parcendum Mollis-TEXTUM Sarcomas Distal in extremo sita est. |
| A tempus de studio I-boost heterologae primi vaccination in quibus HER1 mutilum fit, sic in aegris cum HER2 expressing pectus cancer. |
| Quia grassentur Plasma Pure Biomarkers TSU LXVIII-, et Orat Antiangiogenic agens in Metastasico ad aegroti pectus Cancer. |
| De significatione Intratumoral Clinicopathologic ad homogeneitatem eorundem HER2 Gene amplificatio in HER2 sermonem habuit ad aegroti pectus Cancer-Positive adjuvant trastuzumab |
| Responsum invicem comparatione Pathologic post expendendo Systems Anthracycline cum / sine Taxane Neoadjuvant Plasmodium falciparum-Substructio in diversis subtypes pectus carcinomata |
| N1 processibus mobilitatis et alta coetus B1 (HMGB1 et HMGN1) coniungitur cum pectus cancer tumor-positivum infiltrating lymphocytes, in HER2 |
| Significationem et lymphocytes infiltrating pronostico tumor-Tertiariis LECOMTE Structures in HER2 Pectus Cancer-Positive sermonem habuit ad trastuzumab adjuvant. |
| Pronostico TEXTUS biomarker exploratio cum aegris metastatic renum vascularium endothelial cell carcinoma, quod accipiens incrementum elementum receptor inhibitors discoideum. |
